Coherus BioSciences Gets FDA Approval for Loqtorzi, Chemotherapy Combination
By Sabela Ojea
Coherus BioSciences and Shanghai Junshi Biosciences said the U.S. Food and Drug Administration approved its Loqtorzi antibody to treat nasopharyngeal cancer when used with chemotherapy.
The biotechnology companies said Loqtorzi said is aimed at patients with metastatic nasopharyngeal cancer.
The FDA backed Loqtorzi in combination with chemotherapy drugs cisplatin and gemcitabine.
Loqtorzi is expected to be available in the U.S. in the first quarter of 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 27, 2023 15:54 ET (19:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks